1. We suggest that it is reasonable to prescribe OAC therapy for patients with age ≥65 years or CHADS₂ ≥1 (“CCS algorithm”) who have episodes of SCAF lasting >24 hours, or for shorter episodes in high risk patients (such as those with a recent cryptogenic stroke). (Conditional Recommendation, Low Quality Evidence)